This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
View All Zacks #1 Ranked Stocks
Zacks News
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up
by Zacks Equity Research
Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.
RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data
by Zacks Equity Research
Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.
KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?
by Zacks Equity Research
KalVista jumps 36% in a week after the FDA clears Ekterly, the first oral on-demand therapy for hereditary angioedema.
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study
by Zacks Equity Research
Shares of ProKidney jump 515% after its kidney cell therapy shows strong efficacy in a Phase II diabetes-related CKD study.
Are Medical Stocks Lagging Amarin (AMRN) This Year?
by Zacks Equity Research
Here is how Amarin (AMRN) and Abbott (ABT) have performed compared to their sector so far this year.
Moderna Stock Gains on Encouraging Flu Vaccine Data
by Zacks Equity Research
MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.
Best Momentum Stock to Buy for June 27th
by Zacks Equity Research
GTX, LPG and AMRN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 27, 2025.
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU
by Zacks Equity Research
AMRN jumps 27% after inking an exclusive EU licensing deal with Recordati to expand Vazkepa's reach and cut costs.
Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag
by Zacks Equity Research
Sanofi's riliprubart gets FDA orphan drug status for organ transplant rejection, unlocking key development perks.
Amarin (AMRN) Soars 27.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Amarin (AMRN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.